The therapy binds to CD3 receptors on T cells, activating them and directing them past the blood-brain barrier to tumors.
The firm has struck a deal for clinical-grade manufacturing of its diabetes gene therapy, which it will use within IND-enabling and clinical trials.
The company's successful talks with the pan-Canadian Pharmaceutical Alliance could improve access to the drug for HER2-positive breast cancer patients.
The Center for Transformative Therapeutics is setting up infrastructure so different departments aren't reinventing the wheel ...
Researchers found that NGS testing use rose only slightly in the years after CMS began covering the tests nationally for ...
The rise of expensive precision therapies has spawned a growing industry of auxiliary health benefit companies promising to ...
Despite the firm's ambition to gain approval in all comers, experts were unconvinced of the data on daraxonrasib's efficacy in RAS-wildtype, RAS G13-mutant, or RAS G61-mutant tumors.
Genglycos is the company's first approved gene therapy and is the first commercial gene therapy to treat glycogen storage disease type Ia.
NEW YORK – Merck and Moderna announced Wednesday that a Phase III melanoma trial of Keytruda (pembrolizumab) and the personalized cancer vaccine intismeran autogene has met two key endpoints.
NEW YORK – CARsgen made waves in June when it secured the world's first approval for a CAR T-cell therapy for solid tumors in China, and the company now wants to expand access globally. The autologous ...
The firms will evaluate Ideaya's IDE892 with Genetech's GDC-7035 in MTAP-deleted, KRAS G12D-mutant pancreatic cancer.
Results that may be inaccessible to you are currently showing.
Hide inaccessible results